Ceribell initiated with a Strong Buy at Raymond James

Raymond James analyst Jayson Bedford initiated coverage of Ceribell (CBLL) with a Strong Buy rating and $19 price target Ceribell is pioneering the rapid EEG market with differentiated technology that improves outcomes for patients and providers, says the analyst, who sees “consistent execution” as “disconnected from stock price performance” with shares down 51% year-to-date. The firm says its rating is “not a call” on Q3 results, but its belief that the valuation does not match the financial profile and “gives little credit for current (and pipeline) opportunities.”